Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> GILEAD SCIENCES Latest News

14 HOURS AGO - Investopedia

A Must Read - Share

Ignore These Risks to Gilead at Your Peril

Gilead Sciences (NASDAQ: GILD) has enjoyed remarkable success in the past year thanks to the launch of two instant billion-dollar blockbuster hepatitis C therapies, however, even best-in-breed biotech stocks like Gilead Sciences still face risks that could leave investors in the lurch.

Tags: Ignore These Risks to Gilead at Your Peril,  Gilead Sciences Latest News

APR 18, 2015 - Benzinga

A Must Read - Share

Morningstar: Gilead Sciences To Grow Its Hepatitis C Market

Karen Andersen was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick. Latest Ratings for GILD DateFirmActionFromTo Feb 2015Credit SuisseDowngradesOutperformNeutral Feb 2015CitigroupMaintainsBuy Feb 2015UBSMaintainsBuy View More Analyst Ratings for GILD View the Latest Analyst Ratings

Tags: Morningstar: Gilead Sciences To Grow Its Hepatitis C Market,  Gilead Sciences Latest News

APR 17, 2015 - Washington Business Journal

A Must Read - Share

This company doubled its Foster City office investment in 4 years

What happens when you lure a pharmaceutical giant to rent your entire building amid a red-hot real estate market? You double your money. That’s the coup Boston-based TA Associates Realty just made, selling Foster City’s 101 Lincoln Centre Dr. to Travelers Insurance this week for $58 million, or $362 a square foot, according to property records. That flip comes after ...

Tags: This company doubled its Foster City office investment in 4 years,  Gilead Sciences Latest News

APR 17, 2015 - TheStreet

A Must Read - Share

Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech

BOSTON (TheStreet) -- In this week's Biotech Stock Mailbag, Ron D. emails, "Do you expect Bluebird Bio to have the same positive results in sickle cell disease that they had with beta-thalassemia? When will the company tell us about its sickle cell patients and is there a way for ordinary investors to figure out what is good or not?" I ...

Tags: Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech,  Gilead Sciences Latest News

APR 14, 2015 - Investopedia

A Must Read - Share

How Gilead Plans to Keep Competitors in Check

Gilead Sciences (NASDAQ: GILD) has plenty of experience in outmaneuvering competitors. After all, despite competitors' launching new HIV therapies, Gilead Sciences continues to maintain its dominance in the indication. Whether or not Gilead Sciences can leverage its experience in HIV to protect its market share in hepatitis C is being put to the test this year, so let's take a ...

Tags: How Gilead Plans to Keep Competitors in Check,  Gilead Sciences Latest News